Back to top
more

Integer Holdings (ITGR)

(Delayed Data from NYSE)

$106.52 USD

106.52
379,870

-1.99 (-1.83%)

Updated Aug 1, 2025 03:59 PM ET

After-Market: $106.51 -0.01 (-0.01%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.75%
2Buy17.82%
3Hold9.58%
4Sell5.28%
5Strong Sell2.61%
S&P50011.30%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

2-Buy of 5   2      

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

  • Value Score A
  • Growth Score A
  • Momentum Score A
  • VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

B Value C Growth B Momentum B VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Bottom 35% (159 out of 246)

Industry: Medical - Instruments

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Zacks News

Zacks Equity Research

Medtronic Q4 Earnings and Revenues Top, Stock Down in Pre-market

by Zacks Equity Research

MDT delivers strong fourth-quarter fiscal 2025 results, with significant improvements in both gross and operating margins.

Zacks Equity Research

Is it the Right Time to Hold STERIS Stock in Your Portfolio?

by Zacks Equity Research

STE stays on investors' radars due to the strength of its Healthcare arm and strong rebound potential in the AST segment.

Zacks Equity Research

Factors That Make Centene Stock a Lucrative Pick Right Now

by Zacks Equity Research

CNC remains well-poised for growth on improved premiums, a well-performing Commercial Marketplace business, strategic divestitures and sound cash reserves.

Zacks Equity Research

SYK Stock Likely to Rise Following FDA Clearance for OptaBlate System

by Zacks Equity Research

Stryker secures FDA clearance for OptaBlate BVN, a groundbreaking nerve ablation system designed to treat chronic vertebrogenic lower back pain with precision and safety.

Zacks Equity Research

BD Stock May Rise Following the Launch of FACSDiscover A8 Platform

by Zacks Equity Research

BDX unveils the BD FACSDiscover A8, a next-gen cell analyzer with spectral flow cytometry and real-time imaging, enabling deeper insights into cell function and biology.

Zacks Equity Research

Here's Why You Should Retain Ecolab Stock in Your Portfolio Now

by Zacks Equity Research

ECL continues to gain from its robust product portfolio and strong segmental performance.

Zacks Equity Research

GEHC Stock May Rise Following the Launch of AI-Based CleaRecon DL

by Zacks Equity Research

GE HealthCare launches CleaRecon DL, an AI-powered 3D imaging tech that enhances cone-beam CT scans by reducing artifacts, improving clarity for better interventional care.

Zacks Equity Research

GE HealthCare Stock May Gain as FDA Approves Optison for Pediatric Use

by Zacks Equity Research

GEHC's Optison ultrasound agent receives FDA approval for pediatric use, improving echocardiogram clarity and advancing heart diagnostics for children with safer imaging.

Zacks Equity Research

Here's Why You Should Hold Accuray Stock in Your Portfolio for Now

by Zacks Equity Research

ARAY continues to witness strength in its flagship, CyberKnife system, along with robust global performance.

Zacks Equity Research

STE Q4 Earnings Beat, Margins Expand, Stock Up in Aftermarket

by Zacks Equity Research

STERIS' fourth-quarter fiscal 2025 results reflect strong growth momentum in Healthcare and AST revenues.

Zacks Equity Research

Alcon Q1 Earnings Miss Estimates, Stock Down, 2025 EPS View Lowered

by Zacks Equity Research

ALC ends the first quarter of 2025 on a disappointing note.

Zacks Equity Research

DaVita Stock Down Despite Q1 Earnings Beat, Margins Contract

by Zacks Equity Research

Strength in revenue per treatment and dialysis patient service revenues drives DVA's first-quarter 2025 performance despite a year-over-year decline in normalized non-acquired treatment.

Zacks Equity Research

Prestige Consumer Stock Up 8% Since Q4 Earnings Beat, Margin Increase

by Zacks Equity Research

PBH experiences steady international growth in the fourth quarter, banking on strong sales of the Hydralyte brand.

Zacks Equity Research

GEHC Stock Surges as SIGNA Sprint MRI Redefines 1.5T Imaging Tech

by Zacks Equity Research

GE HealthCare unveils SIGNA Sprint MRI, a high-performance 1.5T system designed to boost diagnostic accuracy, accelerate imaging, and advance cardiac and cancer care.

Zacks Equity Research

PACB Stock May Rise Following the Deal With Chulalongkorn University

by Zacks Equity Research

PacBio and Chulalongkorn University launch Asia Pacific's first population-scale HiFi WGS newborn screening program, advancing precision medicine in Thailand.

Zacks Equity Research

Insulet Q1 Earnings Top Estimates, Stock Up, 2025 Sales View Raised

by Zacks Equity Research

PODD delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

HAE Stock Gains on Q4 Earnings and Revenue Beat, Margins Up

by Zacks Equity Research

Haemonetics' fourth-quarter fiscal 2025 results reflect the positive impact of its long-term plan, with meaningful earnings growth and margin expansion.

Zacks Equity Research

GMED Q1 Earnings & Revenues Miss, '25 EPS View Down, Stock Falls

by Zacks Equity Research

GMED's first-quarter 2025 weak performance reflects soft Enabling Technology deal closures.

Zacks Equity Research

Veracyte Stock Gains on Q1 Earnings and Revenue Beat, Gross Margin Up

by Zacks Equity Research

VCYT registers robust growth from its market-leading Decipher Prostate and Afirma tests in the first quarter of 2025.

Zacks Equity Research

TMDX Stock Gains Post Q1 Earnings & Revenue Beat, Gross Margin Down

by Zacks Equity Research

Increased organ utilization in liver and continued OCS adoption across both liver and heart boosted TransMedics' first-quarter 2025 performance.

Zacks Equity Research

AMN Stock Gains Following Q1 Earnings & Revenue Beat, Margins Down

by Zacks Equity Research

AMN Healthcare's dismal results in all its segments led to a soft overall first-quarter 2025 performance.

Zacks Equity Research

PacBio Stock Down Despite Q1 Earnings & Revenue Beat Estimates

by Zacks Equity Research

Despite strong Service and other revenues, PACB reports soft first-quarter 2025 results partly due to lower Revio system shipments.

Zacks Equity Research

Illumina Q1 Earnings Top Estimates, Revenues Down Y/Y, Stock Dips

by Zacks Equity Research

ILMN delivers better-than-expected earnings and revenues in the first quarter of 2025.

Zacks Equity Research

QuidelOrtho Stock Gains Following Q1 Earnings Beat, Margins Expand

by Zacks Equity Research

Despite solid performances by the Labs and Immunohematology units and EMEA and Other regions, QDEL reports soft overall top-line results in first-quarter 2025.

Zacks Equity Research

INGN Stock Gains Following Q1 Earnings Beat, Revenues Up Y/Y

by Zacks Equity Research

Inogen's overall first-quarter 2025 results continue to gain from higher business-to-business sales.